{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:43:52Z","timestamp":1773024232240,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1208\/s12248-020-00467-8","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T21:03:35Z","timestamp":1592859815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer"],"prefix":"10.1208","volume":"22","author":[{"given":"Manisit","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leaf","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"467_CR1","unstructured":"Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. (eds). SEER Cancer Statistics Review. National Cancer Institute Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission 1975\u20132016."},{"issue":"17","key":"467_CR2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605\u201317.","journal-title":"N Engl J Med"},{"key":"467_CR3","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2147\/OTT.S105587","volume":"9","author":"H Zhang","year":"2016","unstructured":"Zhang H. Onivyde for the therapy of multiple solid tumors. Onco Targets Ther. 2016;9:3001\u20137.","journal-title":"Onco Targets Ther"},{"key":"467_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17:153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"467_CR5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","volume":"12","author":"LP Jordheim","year":"2013","unstructured":"Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12(6):447\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"467_CR6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"L de Sousa Cavalcante","year":"2014","unstructured":"de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol. 2014;741:8\u201316.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"467_CR7","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1021\/bc200173e","volume":"22","author":"TH Senanayake","year":"2011","unstructured":"Senanayake TH, Warren G, Vinogradov SV. Novel anticancer polymeric conjugates of activated nucleoside analogues. Bioconjug Chem. 2011;22(10):1983\u201393.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"467_CR8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.4.4.581","volume":"4","author":"P Karasek","year":"2003","unstructured":"Karasek P, Skacel T, Kocakova I, Bednarik O, Petruzelka L, Melichar B, et al. Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. Expert Opin Pharmacother. 2003;4(4):581\u20136.","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"467_CR9","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1158\/1535-7163.MCT-06-0025","volume":"5","author":"T Oguri","year":"2006","unstructured":"Oguri T, Achiwa H, Sato S, Bessho Y, Takano Y, Miyazaki M, et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther. 2006;5(7):1800\u20136.","journal-title":"Mol Cancer Ther"},{"issue":"1 Suppl 1","key":"467_CR10","first-page":"11","volume":"22","author":"RS Benjamin","year":"1995","unstructured":"Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol. 1995;22(1 Suppl 1):11\u20133.","journal-title":"Semin Oncol"},{"issue":"22","key":"467_CR11","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51(22):6110\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"467_CR12","first-page":"533","volume":"52","author":"V Heinemann","year":"1992","unstructured":"Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52(3):533\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"467_CR13","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/nar\/gkr681","volume":"40","author":"V Allain","year":"2012","unstructured":"Allain V, Bourgaux C, Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res. 2012;40(5):1891\u2013903.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"467_CR14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.nano.2011.02.012","volume":"7","author":"S Rejiba","year":"2011","unstructured":"Rejiba S, Reddy LH, Bigand C, Parmentier C, Couvreur P, Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine. 2011;7(6):841\u20139.","journal-title":"Nanomedicine"},{"issue":"11","key":"467_CR15","doi-asserted-by":"crossref","first-page":"10785","DOI":"10.1021\/acsnano.8b01573","volume":"12","author":"C Du","year":"2018","unstructured":"Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, et al. Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 ( BRCA2) mutation. ACS Nano. 2018;12(11):10785\u201396.","journal-title":"ACS Nano"},{"issue":"5","key":"467_CR16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/adfm.201401583","volume":"25","author":"F Li","year":"2015","unstructured":"Li F, Zhao X, Wang H, Zhao R, Ji T, Ren H, et al. Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv Funct Mater. 2015;25(5):788\u201398.","journal-title":"Adv Funct Mater"},{"issue":"3","key":"467_CR17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","volume":"142","author":"J Li","year":"2010","unstructured":"Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release. 2010;142(3):416\u201321.","journal-title":"J Control Release"},{"issue":"8","key":"467_CR18","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2013.120","volume":"21","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Schwerbrock NM, Rogers AB, Kim WY, Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther. 2013;21(8):1559\u201369.","journal-title":"Mol Ther"},{"issue":"13","key":"467_CR19","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1016\/j.biomaterials.2013.01.063","volume":"34","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Kim WY, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials. 2013;34(13):3447\u201358.","journal-title":"Biomaterials."},{"key":"467_CR20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jconrel.2014.03.016","volume":"182","author":"J Zhang","year":"2014","unstructured":"Zhang J, Miao L, Guo S, Zhang Y, Zhang L, Satterlee A, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release. 2014;182:90\u20136.","journal-title":"J Control Release"},{"issue":"33","key":"467_CR21","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.biomaterials.2013.07.050","volume":"34","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials. 2013;34(33):8459\u201368.","journal-title":"Biomaterials."},{"issue":"3","key":"467_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymthe.2018.11.012","volume":"27","author":"M Das","year":"2019","unstructured":"Das M, Shen L, Liu Q, Goodwin TJ, Huang L. Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer. Mol Ther. 2019;27(3):507\u201317.","journal-title":"Mol Ther"},{"issue":"7","key":"467_CR23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.7150\/thno.14689","volume":"6","author":"AB Satterlee","year":"2016","unstructured":"Satterlee AB, Huang L. Current and future theranostic applications of the lipid-calcium-phosphate nanoparticle platform. Theranostics. 2016;6(7):918\u201329.","journal-title":"Theranostics."},{"issue":"6","key":"467_CR24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0b013e31827ab4c4","volume":"18","author":"CB Westphalen","year":"2012","unstructured":"Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J. 2012;18(6):502\u201310.","journal-title":"Cancer J"},{"issue":"1","key":"467_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.09.037","volume":"279","author":"CE Clark","year":"2009","unstructured":"Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 2009;279(1):1\u20137.","journal-title":"Cancer Lett"},{"issue":"19","key":"467_CR26","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","volume":"67","author":"CE Clark","year":"2007","unstructured":"Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518\u201327.","journal-title":"Cancer Res"},{"key":"467_CR27","doi-asserted-by":"crossref","unstructured":"Zheng L. Immune defects in pancreatic cancer. Ann Pancreat Cancer. 2018;1.","DOI":"10.21037\/apc.2018.11.01"},{"issue":"2","key":"467_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00262-017-2079-7","volume":"67","author":"Q Liu","year":"2018","unstructured":"Liu Q, Zhu H, Liu Y, Musetti S, Huang L. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother. 2018;67(2):299\u2013310.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"467_CR29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/jpet.118.254797","volume":"370","author":"M Das","year":"2019","unstructured":"Das M, Huang L. Liposomal nanostructures for drug delivery in gastrointestinal cancers. J Pharmacol Exp Ther. 2019;370(3):647\u201356.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"467_CR30","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1021\/acsnano.7b01786","volume":"11","author":"L Miao","year":"2017","unstructured":"Miao L, Li J, Liu Q, Feng R, Das M, Lin CM, et al. Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer. ACS Nano. 2017;11(9):8690\u2013706.","journal-title":"ACS Nano"},{"issue":"5933","key":"467_CR31","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457\u201361.","journal-title":"Science."},{"key":"467_CR32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fimmu.2019.00542","volume":"10","author":"S Spear","year":"2019","unstructured":"Spear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, et al. Discrepancies in the tumor microenvironment of spontaneous and orthotopic murine models of pancreatic cancer uncover a new immunostimulatory phenotype for B cells. Front Immunol. 2019;10:542.","journal-title":"Front Immunol"},{"issue":"3","key":"467_CR33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.immuni.2017.08.018","volume":"47","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47(3):597.","journal-title":"Immunity."},{"issue":"21","key":"467_CR34","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1158\/0008-5472.CAN-16-2833","volume":"77","author":"Z D'Costa","year":"2017","unstructured":"D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, Gomes AL, et al. Gemcitabine-induced TIMP1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer. Cancer Res. 2017;77(21):5952\u201362.","journal-title":"Cancer Res"},{"issue":"1","key":"467_CR35","doi-asserted-by":"crossref","first-page":"12000","DOI":"10.1038\/s41598-018-30437-2","volume":"8","author":"SK Deshmukh","year":"2018","unstructured":"Deshmukh SK, Tyagi N, Khan MA, Srivastava SK, Al-Ghadhban A, Dugger K, et al. Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. Sci Rep. 2018;8(1):12000.","journal-title":"Sci Rep"},{"issue":"3","key":"467_CR36","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128\u201341.","journal-title":"Cancer Res"},{"issue":"29","key":"467_CR37","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1038\/onc.2013.357","volume":"33","author":"N Weizman","year":"2014","unstructured":"Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene. 2014;33(29):3812\u20139.","journal-title":"Oncogene."},{"issue":"4","key":"467_CR38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.mpa.0000297723.08005.26","volume":"35","author":"MP Kim","year":"2007","unstructured":"Kim MP, Shah AN, Parikh NU, Gallick GE. Gemcitabine resistance in pancreatic cancer cells is associated with increased expression of stem cell-like markers and a concomitant down-regulation of PTEN and activation of AKT. Pancreas. 2007;35(4):409.","journal-title":"Pancreas."},{"issue":"7\u20138","key":"467_CR39","first-page":"900","volume":"9","author":"HK Le","year":"2009","unstructured":"Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7\u20138):900\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"467_CR40","doi-asserted-by":"crossref","first-page":"e1331807","DOI":"10.1080\/2162402X.2017.1331807","volume":"6","author":"Z Wang","year":"2017","unstructured":"Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6(7):e1331807.","journal-title":"Oncoimmunology."},{"key":"467_CR41","doi-asserted-by":"crossref","unstructured":"Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. 2016;1(14).","DOI":"10.1172\/jci.insight.88328"},{"key":"467_CR42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","volume":"102","author":"X Zhao","year":"2016","unstructured":"Zhao X, Yang K, Zhao R, Ji T, Wang X, Yang X, et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016;102:187\u201397.","journal-title":"Biomaterials."},{"issue":"5","key":"467_CR43","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","volume":"11","author":"K Hu","year":"2017","unstructured":"Hu K, Miao L, Goodwin TJ, Li J, Liu Q, Huang L. Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano. 2017;11(5):4916\u201325.","journal-title":"ACS Nano"},{"issue":"1","key":"467_CR44","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/s41467-018-05906-x","volume":"9","author":"X Han","year":"2018","unstructured":"Han X, Li Y, Xu Y, Zhao X, Zhang Y, Yang X, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat Commun. 2018;9(1):3390.","journal-title":"Nat Commun"},{"issue":"7","key":"467_CR45","first-page":"3861","volume":"35","author":"Y Kuramitsu","year":"2015","unstructured":"Kuramitsu Y, Wang Y, Kitagawa T, Tokuda K, Akada J, Tokunaga M, et al. High-mobility group box 1 and mitogen-activated protein kinase activated protein kinase-2 are up-regulated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res. 2015;35(7):3861\u20135.","journal-title":"Anticancer Res"},{"issue":"2","key":"467_CR46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0300060512474128","volume":"41","author":"C Zheng","year":"2013","unstructured":"Zheng C, Jiao X, Jiang Y, Sun S. ERK1\/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J Int Med Res. 2013;41(2):300\u20136.","journal-title":"J Int Med Res"},{"issue":"8","key":"467_CR47","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17(8):1670\u201382.","journal-title":"Mol Cancer Ther"},{"key":"467_CR48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biomaterials.2017.12.015","volume":"158","author":"X Zhao","year":"2018","unstructured":"Zhao X, Wang X, Sun W, Cheng K, Qin H, Han X, et al. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials. 2018;158:44\u201355.","journal-title":"Biomaterials."},{"key":"467_CR49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2014.12.028","volume":"46","author":"X Zhao","year":"2015","unstructured":"Zhao X, Li F, Li Y, Wang H, Ren H, Chen J, et al. Co-delivery of HIF1alpha siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials. 2015;46:13\u201325.","journal-title":"Biomaterials."},{"issue":"37","key":"467_CR50","doi-asserted-by":"crossref","first-page":"24361","DOI":"10.1021\/acsami.6b05534","volume":"8","author":"MT Haynes","year":"2016","unstructured":"Haynes MT, Huang L. Maximizing the supported bilayer phenomenon: liposomes comprised exclusively of PEGylated phospholipids for enhanced systemic and lymphatic delivery. ACS Appl Mater Interfaces. 2016;8(37):24361\u20137.","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-020-00467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-020-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T23:07:09Z","timestamp":1624316829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-020-00467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1208\/s12248-020-00467-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"L.H. is a consultant for PDS Biotechnology, Samyang Biopharmaceutical, Stemirna, and Beijing Inno Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All animal experiments were conducted in compliance with regulations of the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee (IACUC).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}],"article-number":"88"}}